Oral platelet glycoprotein IIb/IIIa inhibition

L. Kristin Newby, Darren K McGuire

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Platelet aggregation plays a central role in the pathogenesis of thrombosis and the acute coronary syndromes. When given intravenously, potent selective antagonists of fibrinogen binding to the glycoprotein (GP) IIb/IIIa receptor, the final common pathway for platelet aggregation, have been effective in the treatment of acute coronary syndromes. Their benefit ceases, however, with the end of the infusion. Aspirin reduces the incidence of secondary vascular events by 25% to 30% after an acute coronary syndrome, and clopidogrel provides modest improvement over aspirin. However, both are relatively weak antiplatelet agents that each block only one of many pathways to platelet activation and surface membrane expression of the competent GP IIb/IIIa receptor. With the success of the intravenous GP IIb/IIIa antagonists in the acute setting, recent interest has focused on the potential benefit of oral GP IIb/IIIa antagonists used long-term for secondary prevention. The oral agents tested in phase III studies thus far have not performed up to expectations, however. The following paper reviews these studies and the implications of their results.

Original languageEnglish (US)
Pages (from-to)372-377
Number of pages6
JournalCurrent Cardiology Reports
Volume2
Issue number5
DOIs
StatePublished - 2000

Fingerprint

Integrin beta3
Platelet Glycoprotein GPIIb-IIIa Complex
Acute Coronary Syndrome
clopidogrel
Platelet Aggregation
Aspirin
Platelet Aggregation Inhibitors
Platelet Activation
Secondary Prevention
Fibrinogen
Blood Vessels
Thrombosis
Membranes
Incidence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Oral platelet glycoprotein IIb/IIIa inhibition. / Newby, L. Kristin; McGuire, Darren K.

In: Current Cardiology Reports, Vol. 2, No. 5, 2000, p. 372-377.

Research output: Contribution to journalArticle

Newby, L. Kristin ; McGuire, Darren K. / Oral platelet glycoprotein IIb/IIIa inhibition. In: Current Cardiology Reports. 2000 ; Vol. 2, No. 5. pp. 372-377.
@article{eb3bd272a2924b48948b3336edc2a372,
title = "Oral platelet glycoprotein IIb/IIIa inhibition",
abstract = "Platelet aggregation plays a central role in the pathogenesis of thrombosis and the acute coronary syndromes. When given intravenously, potent selective antagonists of fibrinogen binding to the glycoprotein (GP) IIb/IIIa receptor, the final common pathway for platelet aggregation, have been effective in the treatment of acute coronary syndromes. Their benefit ceases, however, with the end of the infusion. Aspirin reduces the incidence of secondary vascular events by 25{\%} to 30{\%} after an acute coronary syndrome, and clopidogrel provides modest improvement over aspirin. However, both are relatively weak antiplatelet agents that each block only one of many pathways to platelet activation and surface membrane expression of the competent GP IIb/IIIa receptor. With the success of the intravenous GP IIb/IIIa antagonists in the acute setting, recent interest has focused on the potential benefit of oral GP IIb/IIIa antagonists used long-term for secondary prevention. The oral agents tested in phase III studies thus far have not performed up to expectations, however. The following paper reviews these studies and the implications of their results.",
author = "Newby, {L. Kristin} and McGuire, {Darren K}",
year = "2000",
doi = "10.1007/s11886-000-0049-7",
language = "English (US)",
volume = "2",
pages = "372--377",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Oral platelet glycoprotein IIb/IIIa inhibition

AU - Newby, L. Kristin

AU - McGuire, Darren K

PY - 2000

Y1 - 2000

N2 - Platelet aggregation plays a central role in the pathogenesis of thrombosis and the acute coronary syndromes. When given intravenously, potent selective antagonists of fibrinogen binding to the glycoprotein (GP) IIb/IIIa receptor, the final common pathway for platelet aggregation, have been effective in the treatment of acute coronary syndromes. Their benefit ceases, however, with the end of the infusion. Aspirin reduces the incidence of secondary vascular events by 25% to 30% after an acute coronary syndrome, and clopidogrel provides modest improvement over aspirin. However, both are relatively weak antiplatelet agents that each block only one of many pathways to platelet activation and surface membrane expression of the competent GP IIb/IIIa receptor. With the success of the intravenous GP IIb/IIIa antagonists in the acute setting, recent interest has focused on the potential benefit of oral GP IIb/IIIa antagonists used long-term for secondary prevention. The oral agents tested in phase III studies thus far have not performed up to expectations, however. The following paper reviews these studies and the implications of their results.

AB - Platelet aggregation plays a central role in the pathogenesis of thrombosis and the acute coronary syndromes. When given intravenously, potent selective antagonists of fibrinogen binding to the glycoprotein (GP) IIb/IIIa receptor, the final common pathway for platelet aggregation, have been effective in the treatment of acute coronary syndromes. Their benefit ceases, however, with the end of the infusion. Aspirin reduces the incidence of secondary vascular events by 25% to 30% after an acute coronary syndrome, and clopidogrel provides modest improvement over aspirin. However, both are relatively weak antiplatelet agents that each block only one of many pathways to platelet activation and surface membrane expression of the competent GP IIb/IIIa receptor. With the success of the intravenous GP IIb/IIIa antagonists in the acute setting, recent interest has focused on the potential benefit of oral GP IIb/IIIa antagonists used long-term for secondary prevention. The oral agents tested in phase III studies thus far have not performed up to expectations, however. The following paper reviews these studies and the implications of their results.

UR - http://www.scopus.com/inward/record.url?scp=0034268673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034268673&partnerID=8YFLogxK

U2 - 10.1007/s11886-000-0049-7

DO - 10.1007/s11886-000-0049-7

M3 - Article

C2 - 10980903

AN - SCOPUS:0034268673

VL - 2

SP - 372

EP - 377

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 5

ER -